Algorithm for Modification of Somatic Cancer Evolution

US 9,569,586, assigned to Albert Rubben, covers the field of targeted cancer therapy, and is available for sale through IPApproach.

US Patents

1 granted

Foreign Counterparts

1

Assignee

Albert Rubben

Availability

For Sale

Patents Included

• US 9,569,586↗

• WO 2,013,120,509 A1

Technology Highlights

• The invention provides an algorithm for personalized cancer treatment by targeting genes that are neither oncogenes nor tumor suppressors but have become essential due to structural constraints of cancer genome architecture. These lineage-specific vulnerabilities arise from chromosomal instability and catastrophic rearrangements (chromothripsis) that eliminate molecular or metabolic redundancy in cancer cells while sparing normal cells.
• By comparing serial tumor samples from the same patient, the algorithm reconstructs phylogenetic trees of cancer subclones to detect positive or negative selection and exclude evolutionary dead ends. On the bioinformatic level, it identifies disrupted pathways that lack redundancy in cancer but remain intact in normal cells. This dual approach enables the discovery of novel or repurposed drugs.
• The invention can also be implemented in software programs that predict the natural history of cancer progression in individual patients and the long-term efficacy of specific treatments. Beyond mutation status, it offers the conceptual framework that explains inconsistent clinical responses across cancer entities: why targeting a given mutation succeeds in some contexts but fails in others. By revealing lineage-specific vulnerabilities through genome architecture modeling, it supports rational drug development, treatment prediction, and next-generation precision medicine.
• This platform technology offers significant benefits across pharmaceuticals, healthcare, and information technology by enhancing target discovery, drug development, and clinical decision support.

Overview

IPApproach, LLC is pleased to present the exclusive patent for license or sale "Algorithm for modification of somatic cancer evolution" which includes U.S. Granted Patent US 9,569,586 B2 and its foreign counterparts WO 2,013,120,509 A1 assigned to Albert Rubben. The IP relates to the field of targeted cancer therapy. In particular, the invention relates to the identification of therapeutic target genes in individual cancer patients which do not represent oncogenes or tumor suppressor genes but have become putative therapeutic targets due to constraints of the cancer genome architecture on individual somatic cancer evolution.

The technology disclosed provides the following advantages:

Listing updated August 21, 2026

IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.